Asset Management One Trims Regeneron Pharmaceuticals Stake

The firm sold over 6,000 shares of the biotech company in Q4 2025.

Apr. 19, 2026 at 7:30am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, metallic financial machinery and equipment in shades of gunmetal grey, copper, and steel blue, conceptually representing the complex infrastructure and mechanics of the global financial system.The reduction in one firm's Regeneron stake reflects broader volatility in the biotech sector, but the company's strong institutional backing and innovative pipeline continue to make it an attractive investment.Tarrytown Today

Asset Management One Co. Ltd. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.5% during the fourth quarter of 2025, according to a recent SEC filing. The firm sold 6,358 shares of the biopharmaceutical company's stock, leaving it with 54,181 shares worth $42.3 million at the end of the reporting period.

Why it matters

Regeneron is a major player in the biotech industry, known for its innovative drug discovery technologies and pipeline of biologic therapies. Changes in institutional ownership of the company's stock can provide insights into broader market sentiment and investment trends within the sector.

The details

Asset Management One's reduced stake in Regeneron came amid a broader sell-off in the stock during the fourth quarter. The company's shares fell from a 52-week high of $821.11 in October to $750.57 by the end of the year. Despite the pullback, Regeneron remains a top holding for many institutional investors, with firms like Dodge & Cox, AQR Capital Management, and Caisse de dépôt et placement du Québec maintaining sizable positions.

  • The filing covers the fourth quarter of 2025, ending on December 31st.
  • Regeneron's shares reached a 52-week high of $821.11 in October 2025.

The players

Asset Management One Co. Ltd.

A Japanese asset management firm that reduced its position in Regeneron Pharmaceuticals during the fourth quarter of 2025.

Regeneron Pharmaceuticals, Inc.

A U.S. biotechnology company focused on discovering, developing, and commercializing biologic therapies for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Asset Management One's Regeneron position reflects broader market volatility in the biotech sector, but the company's strong institutional backing and innovative pipeline continue to make it an attractive investment for many fund managers.